Nestlé parts with peanut allergy treatment Palforzia
Peanut allergies proved a tough nut to crack for Nestlé, which announced Monday it has divested its treatment Palforzia to Swiss allergy specialist Stallergenes Greer.
Nestlé acquired Palforzia in its $2.6 billion takeover of Aimmune in 2020, months after the peanut powder pill became the first FDA-approved treatment for peanut allergy. The idea is to gradually expose patients to small but increasing amounts of the allergen to build resistance. Nestlé had high hopes for Palforzia, but CEO Mark Schneider said on an investor call in November that it ended up being more of a “niche therapy” than a blockbuster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.